APPENDIXES



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 63
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda APPENDIXES

OCR for page 63
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda This page in the original is blank.

OCR for page 63
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda A Agenda for the IOM Workshop ''Antiprogestins: Assessing the Science," April 13–14, 1993 APRIL 13 Room 104 Green Building 2001 Wisconsin Avenue, N.W. Washington, D.C. 8:00–8:30 Continental Breakfast, Room 110 8:30–8:45 Welcome to Participants 8:45–9:00 Purpose of the Workshop   Leslie Z. Benet, Ph.D., Chairman Committee on Antiprogestins: Assessing the Science 9:00–10:30 SESSION I. Overview and Background: Background, Development, Mechanism of Action 9:00–9:30 Development and Future Directions in the Development of Steroid Antagonists Étienne-Émile Baulieu, M.D., Ph.D. Professor of Biochemistry School of Medicine University of Paris-Sud Director of Research, INSERM 9:30–10:00 Antiprogestational/Antiglucocorticoid Compounds: Structure-Function Relationships Nancy L. Weigel, Ph.D. Research Associate Professor Department of Cell Biology Baylor School of Medicine

OCR for page 63
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda 10:00–10:30 Discussion of Session I 10:30–10:45 BREAK 10:45–2:15 SESSION II. State of the Science and Research Directions—Uses of Antiprogestins: The Reproductive Cycle 10:45–11:00 Introduction Lynnette K. Nieman, M.D. Senior Investigator, Deputy Clinical Director, Special Assistant to the Scientific Director National Institute of Child Health and Development National Institutes of Health 11:00–11:30 Daily or Luteal Phase Administration: Mechanism of Action of the Antigestagens on the Endometrium David T. Baird, M.D. MRC Clinical Research Professor of Reproductive Endocrinology Center for Reproductive Biology Department of Obstetrics and Gynecology The University of Edinburgh 11:30–12:00 Uses of Antiprogestins Before 63 Days Marc Bygdeman, M.D. Chairman Department of Obstetrics and Gynecology Karolinska Institute Stockholm 12:00–12:15 Uses of Antiprogestins After 63 Days André Ulmann, M.D., Ph.D. Direction; Domaine Thérapeutique Endocrinologie Roussel-Uclaf Romainville, France 12:15–1:30 LUNCH 1:30–1:45 Comments on Session II David Grimes, M.D. Professor and Vice Chair Department of Obstetrics/Gynecology and Reproductive Sciences University of California at San Francisco

OCR for page 63
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda 1:45–2:15 Discussion of Session II 2:15–2:30 BREAK 2:30–4:20 SESSION III. State of the Science and Research Directions: Therapeutic Uses of Antiprogestins 2:30–3:00 Use of Antiprogestin in the Management of Endometriosis and Leiomyoma Samuel S.C. Yen, M.D. Professor and W.R. Persons Chair Department of Reproductive Medicine University of California at San Diego 3:00–3:30 Use of Antiprogestin in the Treatment of Breast Cancer Kathryn B. Horwitz, Ph.D. Departments of Medicine and Pathology Division of Endocrinology University of Colorado Health Sciences Center 3:30–3:50 Animal Models and Studies on the Mode of Action of Antiprogestins in Growth Inhibition of Mammary Tumors David Henderson, Ph.D. Head, Experimental Oncology Schering AG, Berlin 3:50–4:20 Discussion of Session III 4:20–4:50 General Discussion 4:50 p.m. Adjourn for the Day APRIL 14   8:30–9:00 CONTINENTAL BREAKFAST (Room 110) 9:00–10:15 SESSION IV. State of the Science and Research Directions: Therapeutic Uses of Antiglucocorticoids 9:00–9:45 Lynnette K. Nieman, M.D. Senior Investigator, Deputy Clinical Director, Special Assistant to the Scientific Director National Institute of Child Health and Development National Institutes of Health

OCR for page 63
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda 9:45–10:15 Discussion of Session IV 10:15–10:30 BREAK 10:30–10:50 SESSION V. Primate Models for the Study of Antiprogestins in Reproductive Medicine   Gary D. Hodgen, Ph.D. The Howard and Georgeanna Jones Professor of Reproductive Medicine President, The Jones Institute Foundation Eastern Virginia Medical School 10:50–11:00 Discussion of Session V 11:00–11:20 SUMMING UP   Paul F.A. Van Look, M.D., Ph.D. Acting Director Special Programme of Research, Development and Research Training in Human Reproduction World Health Organization, Geneva 11:20–11:45 Late-Breaking Research Issues and Final Comments 11:45 ADJOURN WORKSHOP